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Menkes disease is a multi-systemic copper metabolism disorder caused by mutations
in the X-linked ATP7A gene and characterized by progressive neurodegeneration and
severe connective tissue defects. The ATP7A protein is a copper (Cu)-transporting
ATPase expressed in all tissues and plays a critical role in the maintenance of copper
homeostasis in cells of the whole body. ATP7A participates in copper absorption in the
small intestine and in copper transport to the central nervous system (CNS) across
the blood-brain-barrier (BBB) and blood–cerebrospinal fluid barrier (BCSFB). Cu is
essential for synaptogenesis and axonal development. In cells, ATP7A participates in the
incorporation of copper into Cu-dependent enzymes during the course of its maturation
in the secretory pathway. There is a high degree of homology (>80%) between the
human ATP7A and murine Atp7a genes. Mice with mutations in the Atp7a gene, called
mottled mutants, are well-established and excellent models of Menkes disease. Mottled
mutants closely recapitulate the Menkes phenotype and are invaluable for studying Cu-
metabolism. They provide useful models for exploring and testing new forms of therapy
in Menkes disease. Recently, non-mammalian models of Menkes disease, Drosophila
melanogaster and Danio rerio mutants were used in experiments which would be
technically difficult to carry out in mammals.
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INTRODUCTION
Animal models are valuable tools for studying the role of copper (Cu) in various physiological, as
well as pathological processes, such as neuro- and embryo development, inflammation and cancer
(Lutsenko et al., 2007; Barry et al., 2010; Collins and Klevay, 2011). Over the last two decades, major
progress has been made in our understanding of the molecular basis of Cu homeostasis, as well as in
identifying the structure and function of Cu-containing proteins, largely thanks to animal models
(Barry et al., 2010; Collins and Klevay, 2011; Telianidis et al., 2013).
MOTTLED MICE AS AN ANIMAL MODEL FOR MENKES DISEASE
Much of our knowledge originates from studies on mice with mutations in the mottled
locus encoding the Atp7a gene (Kodama et al., 1993; Iwase et al., 1996; Kuo et al., 1997;
La Fontaine et al., 1999; Niciu et al., 2007; Lenartowicz et al., 2010). Mouse models of
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Atp7a dysfunction are of particular importance for medical
studies because mutations in the homolog human gene, ATP7A
lead to the metabolic syndrome called Menkes disease, a fatal
metabolic syndrome in humans (Menkes et al., 1962). The
humane gene ATP7A and the murine gene Atp7a are both
located on the X-chromosomes, and encode proteins called
ATP7A, which belong to the P-type ATPase family. ATP7A
transports Cu across membranes. During the catalytic cycle,
ATP7A is autophosphorylated at a conserved aspartic acid
and subsequently binds Cu to transmembrane domains. After
releasing Cu, ATP7A is dephosporylated. ATP7A is located in
the trans-Golgi network (TGN) in the absence of Cu, but recycles
to the plasma membrane in the presence of Cu. It is assumed
that ATP7A located in the TGN is involved in loading Cu on to
Cu-requiring enzymes, whereas ATP7A located in the plasma is
involved in extruding Cu from the cell. The two genes, ATP7A
and Atp7a have a high degree of homology (>80%; Reed and
Boyd, 1997; Kim and Petris, 2007).
The absence of a functional ATP7A transporter does not
alter the Cu uptake, but greatly reduces the efflux of Cu ions
to the extracellular environment (La Fontaine and Mercer,
2007; Lutsenko et al., 2007). ATP7A is the key mediator-
protein involved in Cu transport across epithelial and endothelial
cell barriers, and is therefore crucial for processes such as
intestinal absorption and renal reabsorption of Cu and the
ability of Cu to cross the blood-brain-barrier (BBB; Lutsenko
et al., 2007). About 370 mutations have been identified in
the ATP7A gene in humans, resulting in 3 different clinical
phenotypes of Menkes disease: (1) Classical Menkes disease:
patients with severe symptoms including mental retardation who
die in early childhood (before the age of 6 years); (2) atypical
Menkes disease: patients with less severe symptoms who live
until adolescence; and (3) Occipital Horn Syndrome: patients
with normal or near-normal neurological functions, milder
symptoms, predominantly connective tissue problems, who live
up to mid-adulthood. Furthermore mutations in ATP7A has also
been associated with distal X-linked distal motor neuropathy
(DMN; Kennerson et al., 2010) referred also as X-linked spinal
muscular atrophy type 3 (SMAX-3; Yi and Kaler, 2014). Two
different mutations leading to DMN has so far been identified
(P1386S and T994I). Symptoms appeared when the patient was
between 5 and 50 years of age and include gait instability with
progressive weakness in feet and legs and loss of hand muscles.
In contrast to Menkes disease DMN is not associated with
symptoms of systemic copper deficiency.
A sequence alignment between mouse and human ATP7A
proteins is given in Figure 1. The amino acids sequences
within functional domains are highly conserved between
human and mouse ATP7A (Figure 1). Even between mouse,
human, zebra fish and fruit fly ATP7A/ATP7 proteins, the
functional domains are highly conserved, as demonstrated in
supplementary Figure 1.
Mice with mutations in the Atp7a gene are called mottled
mutants reflecting the pattern of coat pigmentation in
heterozygous females (Cecchi and Avner, 1996). Similarly
to the large number of mutations in the human ATP7A gene,
there are several murine strains with different mutations. The
first description of mottled mutations in mice appeared from
1953 when Fraser and co-authors reported that ‘‘two mice with
mottled coats have been analyzed genetically’’ (Fraser et al., 1953)
and primary defects in copper transport in mottled mutants were
described by Hunt (1974). Now, more than 60 years later and
according to the Mouse Genome Informatics database, 109
mottled alleles are known and nearly half of them (n = 63) were
introduced by gene trapping. Many mottled mutants have arisen
spontaneously (n = 24) or have been induced by chemical (n =
7), chemical and radiation (4), radiation (n = 6), or targeted (n =
7) mutagenesis. Hemizygous mottled males exhibit a severe and
often lethal phenotype. In general, affected males belong to one
of three classes of phenotypic severity: (1) Mutant males that die
in utero; (2) mutant males that die in the 3rd week of postnatal
life; and (3) mutant males that die within a few postnatal months.
So far, mutations in the Atp7a gene have been characterized in
15 mottled mutants (Table 1, Figure 2). The phenotypic diversity
of the mottled alleles is a valuable source of knowledge not only
about the molecular basis of Menkes disease, but also about the
role of Cu in prenatal development.
Prenatal Lethal Mottled Mutants
Eight of the strains have mutations that lead to death in utero
(class 1). This confirms that Cu plays an essential role in prenatal
development, as well as the role of ATP7A in prenatal Cu
metabolism. It has been suggested that mutations in the class
1 mice completely abolish the presence of functional ATP7A
protein leading to the lethality of hemizygous males and the
appearance of several pathological symptoms in heterozygous
females.
Mutations in three strains lead to the absence of at least
one exon in the Atp7a mRNA (Table 1). Fetuses of dappled
(Atp7amo−dp) hemizygous males with the genomic deletion of
exon 1, are seemingly devoid of any Atp7a mRNA. Mutants
display anatomical abnormalities and die already between day 17
and 18 of gestation (Silvers, 1979; Mercer et al., 1994). Mottled
spot (Atp7amo−spot) mutants have a genomic deletion including
exons 11–14 (Cunliffe et al., 2001). A base pair substitution at
the donor splice site of intron 14 leads to a constitutive Skipping
of exon 14 in 1Pub (Atp7amo−pup; Cecchi and Avner, 1996). Male
embryonic lethality at E11 of the tohoku mutants (Atp7amo−tohm)
is caused by a 1440-bp deletion between intron 22 and exon 23 of
the Atp7a gene (Mototani et al., 2006).
Apart from deletions, vast insertions may also be responsible
for lethality (Table 1). In candy (Atp7amo−ca), an insertion of an
81 bp sequence similar to the transposable element LINE in exon
10, leads to the activation of a cryptic splice site, resulting in a
transcript that lacks the first 30 bp of exon 10 (Cunliffe et al.,
2001). Not surprisingly, the nonsense mutation (c.1492G> T,
p.Glu498∗) in Atp7amo−2Btlr is prenatally lethal. Some missense
mutations also lead to prenatal lethality in mice (Table 1).
Miss-localization of ATP7A to the endoplasmic reticulum and
impaired glycosylation of the protein have been shown in H11
(Atp7amo11−H) mutants which were predicted to contain the
amino acid substitution p.Ala1364Asp (Cunliffe et al., 2001; Kim
and Petris, 2007). Also the missense mutation (c.2993C> T
p.Ala998Val) leads to death in utero (REFJ: 133115).
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FIGURE 1 | Sequence alignment between mouse and human ATP7A proteins. Two murine isoforms (NP_001103227.1 (Mouse 1) and NP_033856.3
(Mouse 2) and two human isoforms (NP_000043.4 (Human 1) and NP_001269153.1 (Human 2) are shown. Functional domains: HMA—heavy-metal-associated
domain, TM—transmembrane domain, A-domain—actuator domain, P-domain—phosphorylation domain and corresponding functional motifs: Cu-binding,
phosphatase, phosphorylation, ATP-binding and di-leucine are marked. It should be noted, that the human isoform 2 is shorter than isoform 1 and lacks a part of
TM2 in addition to TM3 and TM4. This product is a result of alternative splicing, leading to skipping of exon 10. Isoform 2 is expressed at low level, in normal healthy
individuals, but has been observed as the major product in a patient with a IVS10 mutation. Because the patient had OHS, in contrast to classic Menkes Disease, it
has been suggested that isoform 2 has partly copper transporting activity (Qi and Byers, 1998). The sequence alignment is performed using Clustal Omega software
(http://www.ebi.ac.uk/Tools/msa/clustalo/). Characteristic protein domains are marked based on conserved domains database (Marchler-Bauer et al., 2015) and
previously published ATP7A protein structures (Kaler, 2011; Tümer, 2013). C. cons. – Clustal Omega consensus. An “∗” (asterisk) indicates positions with fully
conserved residues, a “:” (colon) indicates conservation between groups of strongly similar properties and a (period) indicates conservation between groups of
weakly similar properties.
There is also a group of less well characterized, predominantly
chemically induced, prenatally lethal mottled mutations, which
result in very small amounts of Atp7a transcript (Cecchi et al.,
1997).
Interestingly, whereas wide deletions in the Atp7a gene in
mouse mutant males have a prenatal lethal effect, in humans
about 15% of the mutations in the ATP7A gene, which are caused
by large deletions, in great majority result in the classical, severe
form of Menkes disease leading to death in early childhood
(<6 years; Poulsen et al., 2002; Tümer et al., 2003). It seems
that even the most severe mutations in humans lead to a full-
term pregnancy and live birth. This clearly indicates that the
mutational effects on human ATP7A and mouse Atp7a genes can
be different. These differences may be due to different levels of
efficiency of placental Cu transport or by higher demands in mice
for Cu supply during development.
Mice Models for Classical Menkes Disease
Mutants belonging to the 2nd group are widely used for studies
of Cu metabolism and serve as models of classical Menkes disease
in humans. Especially brindled, mosaic and macular mice have
been studied intensively. Although the genetic background of
the three strains (Atp7amo−br), (Atp7amo−ms) and (Atp7amo−ml)
are different, their phenotypes are very similar (Table 1). In
brindled mutants, the genetic defect is caused by the deletion
of 6 bp in exon 11 which leads to an in-frame deletion of the
amino acids Ala799 and Leu800 located in the region between
the fourth transmembrane domain and the transduction domain
of ATP7A protein (Grimes et al., 1997; La Fontaine et al.,
1999). Although the ATP7A protein level in brindled cells is
very similar to that of control cells, Cu transport activity of
the mutant proteins is extremely reduced. In the brindled cells,
ATP7A is located in TGN independently of the Cu level (note the
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normally Cu-dependent cellular trafficking; La Fontaine et al.,
1999). In the mosaic mutants we identified the missense mutation
c.2933G> C (p.Arg978Pro; Lenartowicz et al., 2012a; Table 1).
Exon 15 encodes the highly conserved 6th transmembrane
domain containing a CPC amino acid motif, which serves as a
channel for Cu(I) transport and is critical for the protein function
(Barry et al., 2010; van den Berghe and Klomp, 2010). In the
mosaic mutants the ATP7A protein is mislocalized and is not
translocated to the plasma membrane regardless of exposure of
these cells to increased Cu concentrations (Lenartowicz et al.,
2012a). Moreover, analysis of the coding region of the Atp7a
gene in the mosaic mutants revealed the presence of the three
additional nucleotides CAG (c.1417insCAG) at the end of exon
4, leading to the addition of a Glutamine between the 4th and
5th Cu-binding domain. This insertion was also associated with
alternative splicing of the 3’ end of the exon 4 (Lenartowicz et al.,
2004). However, this insertion was also found in other inbred
strains of mice and is recognized as a polymorphism (Cecchi
and Avner, 1996). Analysis of the coding region of the Atp7a
gene in macular mutants revealed the mutation c.4223T> C
(p.Ser1382Pro) in the region encoding the conserved 8th trans-
membrane domain (Mori and Nishimura, 1997; Murata et al.,
1997; Table 1). In the macular mutants, impaired Cu delivery
to the secretory pathway is due to hyperphosphorylation of the
ATP7A protein (Kim and Petris, 2007).
In mutants belonging to the 2nd group, the structure of
the Atp7a gene is changed by missense mutations or small in-
frame deletions, which lead to the synthesis of mutated protein
with significantly reduced but not completely abolished activity.
Consequently, hemizygous brindled, mosaic and macular males
manifest pathological symptoms characteristic of strong Cu
deficiency, but they survive until about the 3rd week of life.
Actually, even few brindled and mosaic mutant males survive
a critical period and can achieve remarkable longevity (Silvers,
1979; Lenartowicz et al., 2002; Kowal et al., 2010). Mosaic
mutants that survive are relatively small and display defects
in pigmentation, but do not develop neurological symptoms
(Lenartowicz et al., 2002).
Mottled Models for Occipital Horn
Syndrome
Mutants of the 3rd group exhibit less severe phenotypes and
survive to maturity. Mice in the 3rd group develop pathological
symptoms similar to those described in patients with the atypical
form of Menkes disease and with OHS. Patients with OHS have
less profound neurological manifestations than those suffering
from classical Menkes disease and their clinical features are
mainly restricted to connective tissue defects. They also have a
longer lifespan (Royce and Steinmann, 1990; Proud et al., 1996;
Kaler, 1998; Godwin et al., 2006; Tang et al., 2006; Tümer and
Møller, 2010).
Both viable-brindled and blotchy males manifest strong and
numerous connective tissue abnormalities (Rowe et al., 1974; Das
et al., 1995). The viable-brindled (Atp7amo−vbr) mutants has the
mutation c. 3107A> C in exon 16 (p.Lys1036Thr; Cecchi and
Avner, 1996; Reed and Boyd, 1997). It results in constitutive
post-Golgi localization of ATP7A and is probably caused by
hyperphosphorylation of the mutated protein and significantly
reduced activity (Kim and Petris, 2007). Nevertheless, viable-
brindled males suffer from aortic aneurysms, but they survive
longer than mutants of the 2rd group, and succumb to blood
vessel rupture at the age of 2–3 months (Rowe et al., 1974).
Viable-brindled males are sterile.
The lifespan of blotchy males is the longest among mottled
mutants. However these mutants suffer from emphysema,
develop osteoarthrosis (Silberberg, 1977; Silvers, 1979), aortic
and abdominal aneurysms due to defective elastin fibers (Silvers,
1979; Green, 1981). They usually die from a ruptured aorta at
the age of more than 150 days (Rowe et al., 1974). Their average
survival age is about 200 days and many live longer. Both blotchy
males and females are usually infertile (Silvers, 1979). A splice-
donor mutation is the cause of the defect in blotchy (Atp7amo−blo)
mice (Mercer et al., 1994; Das et al., 1995). The mutation (c.2421
+ 3A> C) in intron 11 leads to partial skipping of 92 bp from
exon 11 and results in a frame-shift (Mercer et al., 1994; Das
et al., 1995; La Fontaine et al., 1999). Blotchy mutants produce,
apart from inactive truncated forms, normal ATP7A protein,
although in significantly reduced amounts. To explain the milder
phenotype of the blotchy mutants it has been shown, that small
amounts of the normal ATP7A protein are synthesized, which
enables a limited Cu absorption and transport (La Fontaine et al.,
1999). Similarly in humans, the less severe (atypical) form of
Menkes disease and OHS are caused mainly by leaky splice-
site mutations, permitting the production of small amounts of
normal transcript (Møller et al., 2009; Skjørringe et al., 2011;
Tümer, 2013). In humans, approximately 22% of mutations
identified in ATP7A gene constitute splice-site mutations (Møller
et al., 2009). However, splice-site mutations can also lead to
the severe form of Menkes disease, if no normal transcript is
produced (Skjørringe et al., 2011). In humans, an estimated 2–5%
of wild-type transcript of the ATP7A gene, alleviates disease
severity resulting in the OHS phenotype (Møller et al., 2000;
Skjørringe et al., 2011).
The connective tissue abnormalities in the mutants are caused
by decreased activity of lysyl oxidase which is responsible for
connective tissue formation (Royce and Steinmann, 1990). Lysyl
oxidase is a Cu-containing extracellular enzyme which catalyzes
the process of oxidative deamination of lysine or hydroxylysine
residues within the collagen α-chains, or of specific lysyl residues
in elastin, to form the aldehyde precursors of the cross-links
necessary to the formation of collagen and elastin (Royce and
Steinmann, 1990; Rucker et al., 1998).
Significant reduction in lysyl oxidase activity has been
demonstrated in skin and aorta (Royce and Steinmann, 1990)
and in the medium of cultured fibroblasts obtained from OHS
and Menkes patients (Kuivaniemi et al., 1985; Kemppainen et al.,
1996).
It is interesting that blotchy mice have more pronounced
connective tissue defects compared to brindled (2nd class
mutant) despite blotchy mutants live much longer. Analysis of
lysyl oxidase activity in extracts from the skin of 10-day old
brindled and blotchy mutants revealed that the enzyme activity in
brindled males was 50–60% of control level whereas it in blotchy
Frontiers in Molecular Neuroscience | www.frontiersin.org 5 December 2015 | Volume 8 | Article 72
Lenartowicz et al. Animal Models of Menkes Disease
FIGURE 2 | Schematic presentation of the secondary structure of the ATP7A protein with location of the 15 mottled mutants indicated. ATP7A is a
transmembrane protein anchored to the membrane of the Golgi apparatus with eight transmembrane domains. The CPC amino acid motif within the 6th
transmembrane domain is assumed to play a direct role in copper ions translocation across the biological membrane. The N-terminal peptide contains six
cytoplasmic copper binding domains. Cytoplasmic domains are involved in the catalytic cycle that mediates cupric ions active transport at the cost of ATP hydrolysis.
In the catalytic cycle ATP was bind to the nucleotide binding domains (N) and after hydrolysis the γ-phosphate of ATP is transferred to the invariant aspartate residue
in the in the phosphorylation domain (P). Energy released by ATP hydrolysis is utilized for ions transport across a membrane. The actuator domain (A) located
between the 4th and 5th transmembrane domains plays a key role in the dephosphorylation of the phosphorylated protein. The amino terminal part of the protein
contains a dileucine motif (LL) motif that is involved in retrograde transport to the trans Golgi network (TGN).
males only was about 30% (Royce et al., 1982). This difference
in lysyl oxidase activity may be explained by different molecular
effect of the mutations. Whereas only small amount of wild type
ATP7A is expressed in blotchy mutants as a result of a leaky
splicesite mutation, normal amount of mutated ATP7A protein,
trapped in TGN as described above, is expressed in brindled
mutants (La Fontaine et al., 1999). The TGN trapped ATP7A
protein probably allowed partial preservation of biosynthetic
functions.
All mottled mutants exhibit defects in pigmentation caused by
decreased activity of tyrosinase, a Cu-dependent enzyme that is
involved in the formation of melanin pigment (Petris et al., 2000).
The catalytic domain of apo-tyrosinase has two Cu-binding sites,
and catalytic activity of tyrosinase requires the incorporation of
Cu into both sites. This process is mediated by ATP7A (Petris
et al., 2000). That is why the fur of the mutant males is uniformly
pale, and the coat pigmentation in heterozygous females, which
are mutation carriers, displays an irregular pattern, probably
due to X chromosome inactivation (Lyon, 1962). Decreased
tyrosinase activity has been found in brindled (Grüneberg, 1969;
Mercer et al., 1999), mosaic (Styrna, 1977) and macular (Yamano
et al., 1987) mutants.
Mice Models for X-Linked Distal Motor
Neuropathy
Conditional knockout mice with selective distruption of the
Atp7a gene in motor neurons (Atp7aMN/Y ) were used to explain
the role of mutation in the ATP7A gene in development
of DMN (Hodgkinson et al., 2015). Knockout mice have a
normal lifespan and do not exhibit signs or symptoms of
systemic copper deficiency characteristic for mottled mutants.
They also have normal coat pigmentation. However during
the lifespan knockout the mice developed gait defects, loss of
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limb strength, and muscle wasting, consistent with the disease
progression observed in DMN patients (Hodgkinson et al.,
2015).
LESSONS FROM THE MOTTLED MICE
Cu Uptake and Distribution
In agreement with the well established role of ATP7A as a
transporter of Cu via the basolateral membrane of enterocytes
(Lutsenko et al., 2007), the defective function of ATPase in
mottled mice leads to the accumulation of Cu in the cytoplasm
of the absorptive epithelial cells in the intestine (Camakaris
et al., 1979; Shiraishi et al., 1988; Kodama, 1993; Nakagawa
et al., 1993). Thus, results from studies in macular mice
reveal a Cu accumulation in the cytoplasm of the intestinal
epithelial cells and in the vascular endothelium (Kodama
et al., 1993). This is consistent with the higher Cu level
found in the small intestine of the brindled (Prohaska, 1983)
and mosaic mutants (Lenartowicz and Sasuła, 2000). The
molecular machinery involved in intestinal Cu transport and
its regulation during early life in healthy mice is poorly
understood.
In mice, the expression of the Atp7a gene begins early in
prenatal life. Atp7a expression has been detected in only 7-day-
old mouse embryos (Cecchi and Avner, 1996). It has been
shown that its expression is ubiquitous during embryogenesis
from day 9.5–18.5 (Kuo et al., 1997). Postnatally, Atp7a is
expressed in all tissues and organs and Atp7a was categorized
as a house-keeping gene (Linz and Lutsenko, 2007; Lutsenko
et al., 2007). However, the expression level differs between
organs and changes during the lifespan (Lenartowicz et al.,
2011).
The pattern of Cu distribution in tissues from mouse models
of Menkes disease cannot be classified as a general, systemic
Cu deficiency. Several tissues such as kidney, intestine, placenta,
and testis, have been shown to accumulate excessive or even
toxic amounts of Cu (Prohaska, 1983, 1988; Phillips et al.,
1986; Nakagawa et al., 1993; Lenartowicz and Sasuła, 2000;
Kowal et al., 2010). This is very likely connected to the
specific function of ATP7A in several cell types, which consists
of expelling Cu from cells to the extracellular environment.
Consequently, dysfunctional ATP7A in absorptive enterocytes
and syncytiotrophoblasts does not only lead to the accumulation
of Cu in these cells, but also limits this metal to other cells in the
body. Furthermore, because ATP7A plays an imported roles in
the delivery of Cu to Cu-containing enzymes, a large number of
essential enzymes are left dysfunctional.
Cu Delivery to the Foetus
During pregnancy, Cu is transported from the maternal to the
foetal circulation via the placenta. This process is mediated by
ATP7A and the homologous Cu-transporting ATPase, ATP7B
(Hardman et al., 2007; La Fontaine and Mercer, 2007). It has
been proposed that ATP7A plays a key role in Cu delivery to the
foetus across the basolateral surface of the syncytiotrophoblast
layer (Hardman et al., 2004, 2007), as an increase in the placental
Cu content is observed in the brindled and macular mouse, and
a direct blockage of placental transport has been demonstrated
in these mouse models (Kasama and Tanaka, 1989; Xu et al.,
1994).
Decreased transport of Cu across the placenta is probably
the first reason for substantially reduced Cu content in the
brain of 1-day-old mosaic mutant mice (Lenartowicz et al.,
2011). Interestingly, wild-type mice and mosaic mutants show
two different profiles of Cu content in the brain during early
development (first 2 weeks after birth) i.e., a substantial increase
is observed in wild-type mice, whereas no changes are found in
mutants. This indicates that neonatal Cu deficiency in the brain
of mutants just after birth is further aggravated throughout the
early development (Lenartowicz et al., 2011).
Cu Disturbance in the Brain
Menkes disease is commonly considered as a neurodegenerative,
Cu deficiency disorder (Tümer and Møller, 2010; Kodama et al.,
2012). In humans, Cu content in the brain (∼5 µg/g tissue) is
among the highest in various tissues (Collins and Klevay, 2011).
This high Cu concentration is related to the metabolic activity
of many Cu-dependent enzymes that function in the brain,
such as cytochrome c oxidase, peptidylglicine alpha-amidating
monooxygenase (PAM), dopamine-beta monooxygenase (DBH)
and Cu, Zn-superoxide dismutase (SOD1; Suzuki and Gitlin,
1999; Prohaska and Broderius, 2006; Lutsenko et al., 2007; Nelson
and Prohaska, 2009).
The ATP7A gene is highly expressed in the ependymal
cells of the choroid plexus, a structure that regulates the
concentration of the different molecules in the cerebro-spinal
fluid, and the ATP7A protein is suggested to be involved
in Cu transport across the BBB (Iwase et al., 1996; Niciu
et al., 2006; Lutsenko et al., 2007). Copper deficiency in the
central nervous system (CNS) of the Menkes patients lead to
delay of their physical and mental development. In Menkes
patients and mottled mutants, Cu accumulates in the cells
comprising the blood-brain barrier and choroid plexus and is
not transported from blood vessels to neuronal tissue (Kodama
et al., 2005, 2012; Donsante et al., 2010, 2011). The severe
decrease in Cu content in the brain and resulting deficiencies
in the activity of Cu-containing enzymes are the main reasons
for the early fatality in Menkes patients as well as in mottled
mice.
ATP7A is especially abundant in the early postnatal
period during brain development, because its activity is
critical for proper axonal development and extension, and
for synaptogenesis (El Meskini et al., 2005; Niciu et al.,
2006, 2007). In the brain, ATP7A is expressed not only in
the neurons, but also in a subset of astrocytes, microglia,
oligodendrocytes, tanycytes and endothelial cells (Niciu et al.,
2006, 2007). Neuropathological changes caused by mutations
in the Atp7a gene are best characterized in brindled mutants.
Due to the lack of activity of Atp7a in the brain of the brindled
mutants the Cu content is 2–4 folds lower when compared
to wild-genotype mice (Camakaris et al., 1979; Phillips et al.,
1986). Detailed analysis of Atp7a/ATP7A expression patterns
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indicates that in the mutant’s brain, both transcript and protein
levels are reduced in Purkinje cells, hippocampal pyramidal
neurons and surrounding interneurons (Niciu et al., 2007).
It resulted in the presence of numerous pycnotic neurons in
the cerebral cortex and hippocampus in the brindled mutants
(Niciu et al., 2007; Donsante et al., 2011). Electron microscopy
examination of the Purkinje cells structure revealed cytoskeleton
disruption, with tortuous, bulbous axons terminating abruptly
in the cerebellar cortex (Niciu et al., 2007; Donsante et al.,
2011). This explains why brindled, mosaic and macular mutant
males in the 2nd week of life manifest severe neurological
symptoms such as tremors, ataxia and seizures (Phillips et al.,
1986; Kodama et al., 2005; Niciu et al., 2006; Lenartowicz et al.,
2012a).
Interesting, neonates Menkes patients do not exhibit any
neurological symptoms but patients older than 2 months
developed seizures, prominent hypotonia and failure to thrive
(Tümer and Møller, 2010; Kaler, 2011). Almost all Menkes
patients older than 2 months developed epilepsy. Seizure types
include focal or multifocal tonic-clonic, myoclonic, infantile
spasms, and status epilepticus (White et al., 1993; Bahi-
Buisson et al., 2006; Kaler et al., 2010). Electroencephalographic
(EEG) analysis indicated that those patients exhibit abnormal
electrocerebral activity (Kaler et al., 2008, 2010). Results
obtained by Kaler et al. (2010) indicated that patients, who
were presymptomatic diagnosed and early treated with copper
injection (≤6 weeks of age), had decreased occurrence of seizures
and improved brain electrical activity. In Menkes patients,
magnetic resonance imaging (MRI) revealed neuropathological
abnormalities including diffuse atrophy, ventriculomegaly,
delayed myelination and tortuosity of cerebral blood vessels
(Kaler et al., 2008; Kaler, 2011). Pathological changes are
especially found in the cerebral cortex and the cerebellum, and
include loss of Purkinje cells and neuronal loss of cerebellar
molecular and internal granule cell layers (Kodama et al.,
2012). In addition, subdural hematomas occurs secondary to
abnormalities in brain arteries due to decreased activities of
lysyl oxidase, which causes neurological damage (Kodama et al.,
2012).
In the mottled mutants, neurological symptoms can also be
caused by disturbances in neurotransmitter production. The Cu-
dependent enzyme, DBH, catalyze the conversion of dopamine
to noradrenaline which is metabolized to adrenaline. In the
cells of patients with Menkes disease, the activity of DBH is
significantly diminished and cannot be improved by parenteral
Cu administration (Christodoulou et al., 1998). These findings
indicate that Cu cannot be incorporated into the apo form
of DBH in MD-affected cells because of ATP7A deficiency
(Kodama et al., 2005). Reduced DBH activity is also found in
the brain of brindled and macular mutants (Wenk and Suzuki,
1983; Kodama et al., 2005; Niciu et al., 2006; Bhadhprasit et al.,
2012). The ratio of noradrenaline to dopamine and adrenaline
to dopamine in these mutants is low when compared to wild-
genotype controls (Kodama et al., 2005; Donsante et al., 2011,
2013; Bhadhprasit et al., 2012).
Another enzyme containing two Cu-centers which cycles
between the Cu(I) and Cu(II) states during catalysis, is PAM
(Steveson et al., 2003; Otoikhian et al., 2012). PAM catalyzes
the C-terminal amidation of about 50% of all glycine-extended
neuropeptides (Steveson et al., 2003; Bousquet-Moore et al.,
2010). Such modification is essential for the bioactivity of
numerous hormones and neuropeptides because it prevent
COOH-terminus ionization and rendering it more hydrophobic.
Such modification allow for better binding of α-amidated
peptides to its receptors (Eipper et al., 1992, 1993; Bousquet-
Moore et al., 2010). Lack of PAM activity in the PAM−/− mice,
lead to lethality during the prenatal life (Bousquet-Moore et al.,
2010; Gaier et al., 2013b). Heterozygous PAM+/− mice are fertile
but developed pathological symptoms such as behavioral deficits,
problems with thermoregulations and increased sensitivity to
drug-induced seizures (Bousquet-Moore et al., 2010; Gaier et al.,
2013b) and disturbance of copper metabolism in the brain
(Gaier et al., 2013b). ATP7A co-locates with PAM in the
intracellular compartments and is required for the maturation of
this cuproprotein by metallation with Cu ions in TGN (Steveson
et al., 2003; El Meskini et al., 2005; Otoikhian et al., 2012).
In the brain of 12-day-old brindled mice, the expression level
of PAM protein is similar to control mice, but the activity is
reduced. In the brindled mutants it is manifested by reduced
amidation of joining peptides, (JP-NH2), cholecystokinin (CCK)
and a diminished level of alpha-melanotropin (alpha-MSH).
Thus, the lack of amidated peptides in many target tissues,
at crucial periods during the development, could contribute
to the disease phenotype (Steveson et al., 2003; Niciu et al.,
2007).
Epilepsy and seizures in Menkes patients and mottled mutants
can be multifactorial processes connected with decreased copper
contents in the CNS leading to deficits in neurotransmitter
function, altered energy metabolism, and excitotoxicity (Prasad
et al., 2011; Gaier et al., 2013a; Verrotti et al., 2014). It is
known that some process of neural excitation and inhibition
are modulated by amidated peptides (Bousquet-Moore et al.,
2010). In vitro analysis of hippocampus slices indicated that the
thyrotropin hormone-releasing hormone (TRP) reduce neuronal
excitation by inhibition of potassium-stimulated glutamate and
aspartate release. TRP analog administration reduce seizures
(Nie et al., 2005; Veronesi et al., 2007; Bousquet-Moore et al.,
2010). Results of immunostaining analysis indicated that both
ATP7A and PAM highly expressed in the GABAergic neurons
(Gaier et al., 2013b). Decreasing activity of PAM in the brain
of the mottled mutants can lead to impaired production of
amidated neuropeptide Y (NPY) and can be responsible for
seizures. NPY decrease glutamate release and results obtained by
Richichi and co-workers indicated that both acute and chronic
seizures can be reduced by increasing NPY expression in the
hippocampus (Richichi et al., 2004; Bousquet-Moore et al., 2010).
Macular and brindled mutants also exhibit reduced cerebral
cytochrom c oxidase activity (Donsante et al., 2011; Munakata
et al., 2012).
The conditional knockout mice with selective disruption of
Atp7a gene in motor neuron were very useful in evaluating the
role of the ATP7A protein in normal motor neuron function.
In (Atp7aMN/Y ) knockout mice deletion of Atp7a resulted in
disturbances of copper transport; copper concentration in the
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motor neurons increased with concomitant decreasing of Cu
contents in the spinal cord. Accumulation of copper in the
motor neurons lead to degeneration of the neuron cells and
especially interesting degeneration process begins in the distal
portions of axons and retreats towards the cell body (Hodgkinson
et al., 2015). This pattern of neuron loss leads to denervation
of the neuromuscular junctions and finally to muscular atrophy
(Hodgkinson et al., 2015).
Hepatic Cu
Examples from studies on iron absorption in rodents clearly
show that the expression of the main apical and basolateral iron
transporters in the duodenum is very low during the neonatal
period (reviewed by Lipi´nski et al., 2013). Interestingly, in mice,
the divalent metal transporter 1 (DMT1/Nramp2), is proposed
in addition to functioning as an apical ferrous iron transporter
(Lutsenko et al., 2007) to play a relevant role in physiological Cu
absorption (Arredondo et al., 2003). DMT1 is barely detectable
at postnatal days 0 and 5, but by day 10 this transporter is
predominantly localized in the apical membrane of the maturing
intestine (Lopez et al., 2006). Similarly to iron, the initial hepatic
Cu stores established through maternal-fetal transfer, determine
the iron status of the newborn.
Cu accumulated in the foetal liver during the second half
of prenatal development is a primary source of this metal for
meeting the needs of the organism during neonatal period
(McArdle and Erlich, 1991; Mercer et al., 1992). Studies on
mosaic mutants clearly show that the Cu content is significantly
decreased already on day 1 after birth and persists at low level
up to day 14 (Lenartowicz et al., 2011). An early decrease in
hepatic Cu concentration has also been reported in other mouse
models of Menkes disease (Prohaska, 1983; Phillips et al., 1986;
Nakagawa et al., 1993). Considering that the liver is an organ
that plays a role in the redistribution of Cu around the body,
hepatic Cu scarcity in early development may result in restricted
Cu supply from the liver to other tissues and organs including
brain, heart or muscles. We recently reported the presence of low
Cu levels in peripheral erythrocytes of 14-day-old mosaic male
mice. This decrease strongly correlates with the down-regulation
of both expression and activity of the Cu-dependent antioxidant
enzyme SOD1, playing a crucial role in erythrocyte antioxidant
defense. SOD1 dysfunction results in oxidative stress, increased
fluidity of erythrocyte membranes and hemeolysis (Lenartowicz
et al., 2014).
Cu in the Kidney
A toxic Cu accumulation in the kidney is observed in most
mouse models of Menkes disease (Suzuki-Kurasaki et al., 1997;
Kirby et al., 1998; Lenartowicz et al., 2001, 2010). There is
evidence that in mottled mice, renal epithelial cells of proximal
tubules are the primary sites of Cu toxicity (Suzuki-Kurasaki
et al., 1997; Kirby et al., 1998). Available data suggest a likely
mechanism for this Cu overload. In the kidneys of healthy
animals, Cu reabsorption from the urine occurs via the proximal
renal tubules. The Cu ions are transferred back to the circulation
via ATP7A, located in the basolateral membranes of epithelial
cells of these tubules. This explains why the dysfunction of
the ATP7A protein results in toxic Cu accumulation at the
renal-proximal epithelium (Suzuki-Kurasaki et al., 1997; Kirby
et al., 1998; Lenartowicz et al., 2010). Our previous results
indicated that Cu accumulation in the kidney starts in prenatal
life because the Cu-concentration in the only 1-day-old mice was
higher than in wild-genotype mice (Lenartowicz et al., 2011).
An increase in the Cu level in the kidney of the 18-day-old
macular fetus was also found by others (Kasama and Tanaka,
1989). We also noticed that the Cu accumulation process in
the kidney is strongly enhanced during the postnatal life of
the mutants, because in 1-day-old mosaic males the Cu level
was increased twofold, whereas it was increased fourfold in 14-
day-old mutants when compared to control mice (Lenartowicz
et al., 2010). It is noteworthy that Cu is even more active
than iron in catalyzing the Fenton reaction. It is not surprising
therefore that the kidneys of mouse Atp7a mutants display a
large range of oxidative damage. Pathological changes involve
renal tubules and glomeruli damage. In some cases the changes
are very serious with renal tubules necrosis and sclerosis of
renal glomeruli (Lenartowicz et al., 2002, 2010). Although
renal pathology is not a direct cause of death in mottled
mice, it constitutes a serious problem during Cu therapy.
Parenteral supplementation with Cu prevents early death of
mice, but at the same time it increases renal Cu content and
strongly exacerbates kidney dysfunction (Lenartowicz et al.,
2001, 2010). Treatment with Cu alone in postnatal life results
in an up to 10-fold increase of Cu in the kidney of 14-
day-old mutants when compared to untreated mosaic mice
(Lenartowicz and Sasuła, 2000). The high Cu concentration
persists during the life span of the treated mutants (Lenartowicz
et al., 2010).
Mottled Mice and Menkes Disease Therapy
Effective therapy is still a topical problem in Menkes disease.
Treatment of Menkes patients with daily Cu injections may
relieve the symptoms, as long as it is started within a few days
after birth (Kaler et al., 2008; Tümer and Møller, 2010; Kodama
et al., 2011, 2012). However, in the severe form of classic Menkes
disease, even early Cu therapy is not always effective, and does
not protect patients from neurological and connective tissue
damage (Nadal and Baerlocher, 1988; Kaler et al., 1995; Choi and
Zheng, 2009; Kodama et al., 2011, 2012).
Mottled mice appear to be a good model for exploring possible
new therapeutic strategies of Cu administration in patients
with Menkes disease. Cu-treatment applied as intraperitoneal or
subcutaneous injections before the 7th day of postnatal life have
been shown to improve the viability of mosaic (Kowal et al.,
2010; Lenartowicz et al., 2010), brindled (Phillips et al., 1986) and
macular mutant males (Shiraishi et al., 1988). Cu-treated mosaic
mutant males survive significantly longer, achieve maturity and
do not manifest neurological problems. Nevertheless, they still
display a defect in pigmentation, and are usually smaller than
control males (Lenartowicz et al., 2010). In both humans and
mice, the BBB is immature during the first days after birth,
and Cu can be pumped to the brain despite the lack of ATP7A
activity. This is a critical period for initiating successful therapy
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(Kodama et al., 2011, 2012). In mice, if therapy starts later than
day 10, almost all mutants die (Mercer et al., 1999).
Therapy in Menkes disease is mainly focused on Cu delivery
to the CNS. A new and effective treatment consists of a
‘‘combined therapy’’, in which Cu is administered together with
lipophilic Cu chelators such as diethyldithiocarbamate (DEDTC)
or dimethyldithiocarbamate (DMDTC). It is noteworthy that Cu
in a lipid-soluble complex with DMDTC or DEDTC has a high
capacity to penetrates the BBB (Tanaka et al., 1990; Kodama
et al., 2005). Experiments performed on macular mice subjected
to CuCl2 therapy on postnatal day 7 followed by combined CuCl2
and DMDTC therapy started at postnatal day 28, indicated that
the combined treatment leads to a significant increase in the
amount of Cu in the brain, and the treated mice survive longer
than untreated ones (Tanaka et al., 1990; Kodama et al., 2005).
We have also obtained very promising results by giving mosaic
mice a CuCl2-DMDTC combined treatment prenatally starting
on day 7 of pregnancy. Mosaic mutant offspring of females
that underwent the combined CuCl2-DMDTC treatment show
increased Cu level in the brain; this effect persists at least into
the 2nd week of postnatal life. Furthermore, prenatal treatment
with Cu compounds in mosaic mice lead to an increase in
survival, improved locomotion performance, and a higher body
mass (Lenartowicz et al., 2012b). Similar results were obtained in
macular mice treated with Cu injections and oral disulfirm from
postnatal day 7 (Bhadhprasit et al., 2012). Disulfirm is a dimer
of DEDTC used for treating alcoholism and cocaine addiction
(Bhadhprasit et al., 2012).
The activity of cytochrome c oxidase is higher in the brain of
the Cu-DEDTC treated macular mutants when compared to the
mutants treated with CuCl2 alone. Analysis of the catecholamine
levels in the brain of the treated mice indicate that the dopamine
levels are lower and the levels of noradrenaline and adrenaline
are higher when compared to untreated mice, indicating that
the DBH activity had improved with the treatment (Kodama
et al., 2005). These findings suggest that DEDTC improves the
transport of Cu to neurons in the brains of mottled mice making
Cu available to Cu-dependent enzymes (Kodama et al., 2005).
Moreover, we and others have observed that the combined
therapy efficiently reduces Cu accumulation in the kidney of
treated mottled mice (Phillips et al., 1991; Tanaka et al., 1990;
Kodama et al., 1993; Lenartowicz et al., 2012b), which might be
a very important effect, considering the accumulation of Cu in
the kidney of mottled mice and Menkes patients as a result of Cu
treatment (Phillips et al., 1991; Kodama et al., 1993; Zaffanello
et al., 2006; Kaler et al., 2008). Cu accumulation in the kidney
induces a strong nephrotoxic effect (Lenartowicz et al., 2002,
2010).
Interestingly, reduced Cu accumulation in the kidney has
also been achieved using the highly lipophilic organic Cu-
complex, Cu-pyruvaldehyde bis(N4-methylthiosemicarbazone;
Cu-PTSM). In the cells, Cu-PTSM is irreversibly reduced and
cleaved to liberate Cu ions which can be incorporated into the
intracellular Cu pools (Fujibayashi et al., 1993; Munakata et al.,
2012). In macular mutants treated with Cu-PTSM, the renal Cu
content was half of the Cu content in CuCl2-treated mutants.
However there were no significant differences in brain Cu levels
between CuCl2 and Cu-PTSM treated mutants, but cytochrome
c oxidase activity was higher in Cu-PTSM treated macular mice
(Munakata et al., 2012).
The next step in developing new effective treatments for
Menkes disease was to study the possibilities of correcting the
mutated ATP7A gene. Brindled mice served as an experimental
model for the construction of transgenic mice that expressed the
human ATP7A gene (Llanos et al., 2006; Donsante et al., 2011).
Recombinant adeno-associated virus encoding a N-terminal
truncated form of ATP7A (containing two instead of six copper
binding sites) was injected into the lateral cerebral ventricles of
neonatal brindled mutants. Transgenic brindled mice survived
significantly longer than untreated mice and were fertile.
However, the coat color and the Cu concentration in the organs
of the rescued mutants resembled those in heterozygous females
(Llanos et al., 2006). These results confirm the high degree
of homology between the mouse and human Atp7a/ATP7A
genes because the human gene was able to correct a genetic
defect in mutant mice. Moreover, mutants treated with CuCl2 in
combination with gene therapy survived even longer and the Cu
level and activity of DBH in the brain was significantly increased,
resulting in the improvement of neuromuscular strength and
balance (Donsante et al., 2011).
INTERACTION BETWEEN CU AND IRON:
LESSONS FROM MOUSE MODELS OF
MENKES DISEASES
The systemic iron homeostasis is maintained by the coordinated
regulation of iron absorption in the duodenum, iron recycling
of senescent erythrocytes in macrophages, and mobilization
of iron stored in the liver. These processes are controlled by
hepcidin, a key iron-regulatory hormone synthesized mainly in
hepatocytes in response to iron stores, erythropoiesis, hypoxia
and inflammation (Viatte and Vaulont, 2009). Hepcidin acts
by posttranslational downregulating of ferroportin (Fpn), the
only known iron exporter. The loss of Fpn decreases the iron
flow into plasma from absorptive enterocytes, macrophages,
and hepatocytes, thereby lowering plasma iron concentrations,
contributing to intracellular iron arrest and thus leading to
functional anemia. Apart from the degradation of Fpn triggered
by hepcidin, multiple regulatory mechanisms control the amount
of cell surface Fpn expression in tissue macrophages and
absorptive enterocytes (Beaumont, 2010).
Some pathways of iron homeostasis largely depend on the
activity of Cu-containing ferroxidases, such as ceruloplasmin
(Cp) and hephastin (Heph). The close relationship between the
biology of Cu and iron in mammals has been recognized and
has for many years mainly been focused on the role of Cp
expressed in macrophages, in facilitating iron recycling from
senescent red blood cells (Collins et al., 2010). In humans,
this process recovers approximately 25 mg iron per day, which
corresponds to the daily requirement of iron for erythropoiesis.
Cp is mainly synthesized in hepatocytes in the form of apo-
Cp. Incorporation of Cu into apo-Cp results in the formation
of the redox-active holoenzyme and is mediated by ATP7B
during transit through the TGN. It has been shown that an
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alternative spliced glycosylphosphatidylinositol (GPI) variant of
Cp (Cp-GPI) originally characterized in the brain (Patel and
David, 1997) is of particular importance for iron metabolism
(Collins et al., 2010; Prohaska, 2011). Cp-GPI cooperates with
Fpn to facilitate the movement of iron out of cells. First, ferrous
ions transported into the circulation by Fpn are oxidized by
Cp-GPI and ferric ions are then bound by transferrin. Second,
Cp-GPI is required for the stability of cell surface Fpn (De
Domenico et al., 2007). The importance of Cp in human iron
homeostasis has been confirmed by the description of the human
congenital disease, aceruloplasminemia, in which mutations in
the ceruloplasmin gene lead to its absence in plasma (Yoshida
et al., 1995). While the anemia observed in humans with
aceruloplasminemia is not severe, severe iron loading is found in
the brain. Humans and mice suffering from aceruloplasminemia
showed a striking impairment in the movement of iron out of
reticuloendothelial cells and hepatocytes (Harris et al., 1995).
It is not surprising therefore that iron-limited erythropoiesis
is the main consequence of Cu deficiency. Metabolic pathways
involving Cu and iron are also linked through the second Cu-
containing ferroxidase Heph, which is implicated in iron efflux
from the intestine (Collins et al., 2010). Heph co-localizes with
Fpn on the basolateral membrane of duodenal enterocytes,
where it stimulates the absorption of dietary iron. The sla (sex-
linked anemia) mice have a defect in the basolateral export
of iron from intestinal enterocytes into the circulation due to
mutation in the hephastin gene, resulting in iron deficiency and
microcytic hypochromic anemia (Vulpe et al., 1999). Systemic
iron deficiency has also been reported in Cu-deficient mice that
display decreased Heph ferroxidase activity in the intestine (Chen
et al., 2006).
Mottled mice seem to be valuable for studying the interaction
between Cu and iron metabolisms in vivo. Systemic iron
homeostasis is mainly established and maintained by four cell
types: intestinal enterocytes, reticuloendothelial macrophages,
hepatocytes and progenitors of red blood cells. In this context,
diverse tissue specific deregulated patterns of Cu content and
distribution in mottled mice may increase our understanding of
Cu-iron interactions at different sites in the body where iron
balance is controlled. Recently, brindled mice served for the first
time as an animal model in which iron homeostasis was studied
(Gulec and Collins, 2013). Specifically, this study referred to the
Cu-related compensatory response of the intestinal epithelium,
the main site of iron entrance into the body in order to protect
against iron deficiency. When brindled mice were deprived
of iron, they developed anemia and enhanced intestinal iron
absorption, similarly to wild-type mice. However, in contrast to
controls, the upregulation of iron absorption in mutant mice was
accompanied by increased enterocyte and hepatic Cu content as
well as by increased serum ferroxidase (Cp) activity (Gulec and
Collins, 2013). Additional mechanistic and molecular aspects of
increased iron absorption in Atp7a mutants have been raised in
rat intestinal epithelial cells (IEC-6), in which the Atp7a gene was
silenced using short hairpin RNA technology. Transepithelial
iron transport was increased in knockdown cells under both
normal and iron-deficient conditions (Gulec and Collins, 2014).
This phenomenon was associated with increased expressions
of duodenal cytochrome b and Fpn involved in intestinal iron
uptake and efflux, respectively (Gulec and Collins, 2014).
In our recent paper we used Cu-deficient mosaic mutants
to investigate metabolic connections between Cu and iron
(Lenartowicz et al., 2014). Mosaic mutant hemizygous males
normally die by day 17 of life (Lenartowicz et al., 2012a) from
severe Cu deficiency; therefore we used 14-day-old animals for
our study. The erythrocytes of these mutants are Cu-deficient,
display decreased activity/expression of the antioxidant enzyme
SOD1, and have cell membrane abnormalities. SOD1 scavenges
the superoxide anion, a reactive oxygen species contributing
to the toxicity of iron via the Fenton reaction (Zelko et al.,
2002). In consequence, the mosaic mice show evidence of
hemolysis accompanied by haptoglobin-dependent elimination
of hemoglobin (Hb) from the circulation, as well as the induction
of heme oxygenase 1 (HO1) in the liver and kidney. Moreover,
the hepcidin-Fpn regulatory axis is strongly affected in mosaic
mice i.e., mutants show increased hepcidin and decreased Fpn
expressions in the liver (Figure 3). Our results show for the first
time the molecular mechanism of the induction of hemolysis by
Cu deficiency and demonstrate how suckling mice adapt their
iron metabolism to hemolytic insult (Lenartowicz et al., 2014).
OTHER ANIMAL MODELS OF MENKES
DISEASE
Danio rerio and Drosophila melanogaster
as Model Organisms of Menkes Disease
Although mottled mice have been a well-established and
characterized mammalian model of Menkes disease for many
years, recently scientists developed new non-mammalian models
for this disorder such as the zebrafish (Danio rerio) and
the fruit fly (Drosophila melanogaster) models. Both species
have served as experimental animals in biology for many
years due to relatively inexpensive maintenance and relative
easiness for genetic manipulation. These new models expand our
understanding of Cu metabolism in the cell and suggest new
therapeutic strategies in Menkes disease.
Cu as a biometal plays a significant role not only in the adult
organism, but it is also crucial in early developmental stages of
humans and mice. It is difficult to follow the pathology of Cu
metabolism during development in mammals. However, taking
these facts into consideration, it seems that ex vivo fertilization,
high fertility rate and rapid development make zebrafish an ideal
model for such research. Embryos of D. rerio developed ex utero
are optically clear, and therefore many of the processes of interest
to the developmental biologist are easily observable. What is
more, the genome of zebrafish has been sequenced and reveals
that many genes and metabolic pathways are highly conserved
between humans and zebrafish (Phillips and Westerfield, 2014).
Danio rerio absorbs Cu in two ways: via the intestine similarly
to what is observed in mammals, and by the gills. Interestingly,
the highest expression of the major Cu importer Ctr1 protein was
detected in gut (Leung et al., 2014). Furthermore, the expression
of Atp7a mRNA is ubiquitous in the zebrafish embryo and
starts early in development (Mendelsohn et al., 2006). Besides
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FIGURE 3 | Interaction between copper (Cu) and iron (Fe) in young mosaic mice. Duodenal enterocytes can export copper across the basolateral membrane
by ATP7A protein. Due to ATP7A gene mutation in mosaic mice, copper cannot be released to the serum and accumulates within the enterocytes in a complex with
metallothionein (MT). Decreased serum Cu level entails Cu deficiency in red blood cells (RBC) and in consequence reduced activity/expression of Cu, Zn-superoxide
dismutase (SOD1), which play a crucial role in RBC antioxidant defense. As the result, Cu-deficient RBC of mosaic mice display morphological abnormalities and
undergo intravascular hemeolysis connected with hemoglobin (Hb) release to the serum and haptoglobin-dependent (Hp) elimination of free Hb from the circulation.
When Hb is released from damaged RBC, it is instantly bound by haptoglobin (Hp) and forms a Hp–Hb high-affinity complex. This complex is then rapidly taken up
from the circulation by the CD163 receptor present mainly on tissue macrophages (in the liver on Browicz-Kupffer cells). The CD163 receptor has no measurable
affinity for free Hp. Thus, specific recognition of Hp–Hb by CD163 explains the decrease in Hp concentration in the serum during accelerated hemeolysis. The
proteolytic Hb degradation in Browicz-Kupffer cells leads to the release of heme, which is then enzymatically decomposed by heme oxygenase 1 (HO-1) resulting in
the formation of carbon monoxide (CO), biliverdin and Fe. Non-heme iron can be then stored as a complex with ferritin (Ft) or exported outside the cell by ferroportin
(FPN), the sole cellular exporter of ionic iron known in mammalian cells. The content of hepatic non-heme Fe is elevated in mosaic mice, probably due to decreased
expression of FPN. The concentration of cell surface Fpn largely depends on the post-translational regulation through internalization and degradation following
hepcidin (Hepc) binding. Down-regulation of FPN expression in the liver of young mosaic mice is probably due to the concomitant up-regulation of hepatic hepcidin
gene (Hamp), synthesized mainly in hepatocytes in response to systemic inflammation reported to occur in mosaic mice.
it is believed that the Atp7a pump is necessary for loading
maternal Cu into the egg (Madsen and Gitlin, 2008). Experiments
have also shown that during embryogenesis Atp7a is responsible
for proper Cu metabolism in individual cells. However Atp7a
may not be essential for Cu transport from the yolk sac or
within the embryo (Mendelsohn et al., 2006). In adult zebrafish,
the expression pattern of Atp7a is similar to that found in
mammalian tissues, such as intestine, kidney, heart, gills and liver
(Chen and Chan, 2011; Leung et al., 2014). Atp7a is expressed
most abundantly in the kidneys under elevated Cu level as
well as under control conditions which suggests a major role
of Atp7a in Cu export in D. rerio similar to observations in
mice (Leung et al., 2014). However, in contrast to mice, in
which Atp7a plays a significant role as a transporter in the
brain barrier systems, glial cells and neurons (Lutsenko et al.,
2010; Zheng and Monnot, 2012), the expression of Atp7a in
the brain of D. rerio is very low (Chen and Chan, 2011).
Surprisingly, in the liver of zebrafish the expression level of
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the Atp7a gene is high compared to the expression level of
Atp7b (Leung et al., 2014), whereas the major Cu-ATPase in
the adult mammalian liver is in fact Atp7b (Lutsenko et al.,
2007). The Atp7a/ATP7A proteins in D. rerio and mammals play
similar roles, and knockdown of the Atp7a gene (Mendelsohn
et al., 2006; Madsen et al., 2008) as well as its inhibition by
antisense oligonucleotide (Chen et al., 2011) result in a lack
of pigmentation and the notochord deformation phenotype in
embryos. These phenotypic effects are probably correlated to
the dysfunction of Cu-dependent enzymes, i.e., tyrosinase and
lysyl oxidase (Mendelsohn et al., 2006). These phenotypic effects
are similar to what is observed in mottled mice (Kim and
Petris, 2007) as well as in Menkes disease patients (Tümer and
Møller, 2010). Moreover, expression of the human ATP7A gene
in Atp7a zebrafish mutants can restore the normal phenotype
(Mendelsohn et al., 2006). These data also confirm a high degree
of conservation of Cu metabolism pathways between mammals
and fish.
Since 2006, in Gitlin’s laboratory, three calamity mutants of
zebrafish: calvu69 (Mendelsohn et al., 2006), calgw246 (Madsen
et al., 2008) and calgw71 (Madsen and Gitlin, 2008), have been
described as novel vertebrate models of Menkes disease. These
strains were generated by N-ethyl-N-nitrosourea mutagenesis,
and mutations in the Atp7a gene were confirmed by sequencing.
Although these mutations are different, the phenotype effects are
similar regarding the presence of notochord defects and the lack
of pigmentation.
The mildest mutation, calgw71 results in a single, non-
conservative amino acid substitution (p.Ile1061Ser) in the region
close to the critical ATP binding residue (Glu1064) of the Atp7a
protein. This single amino acid substitution results in significant
depletion of functional protein in embryos. This calgw71 variant
was, when expressed in fibroblasts obtained from patients with
Menkes disease, able to deliver a suitable amount of Cu to
the human Cu-dependent enzyme—tyrosinase. However, under
Cu-depleted conditions, the activity of tyrosinase was reduced
when compared to complementation with wild-type construct.
Probably the mutated form of Atp7a retains some transport
activity (Madsen and Gitlin, 2008). These data suggest that even
low activity of Atp7a protein is sufficient to maintain an almost
normal phenotype similarly to what we observed in humans
(Møller et al., 2000; Skjørringe et al., 2011). Because the calgw71
animals are viable, it was possible to examine several post-
embryonic effects of this mutation. Surprisingly, under adequate
Cu conditions, adult homozygous mutants of zebrafish did not
display a mutant phenotype, but in the absence of Cu, vertebral
skeletal defects in larva were evident during development. What
is more, treatment of larva with the chelator neocuproine (added
to the water) leads to death, which indicates an increase in
sensitivity to mild Cu deprivation as the embryo develops
(Madsen and Gitlin, 2008).
Gitlin’s group has demonstrated the usefulness of
morpholinos designed for targeting sequences near the mutant
splice sites in order to force correct splicing and thereby correct
aberrant splicing in an embryonic zebrafish (Madsen et al.,
2008). Morpholinos which are oligonuclotides, usually 25 bases
in length, are designed to target the RNA sequence of interest
via complementary base pairing. The oligonuclotides bind
to a target sequence thereby facilitating steric hindrance of
proper transcript processing or translation (Bill et al., 2009).
Injections of morpholino into calamity mutants fully rescue the
Cu-deficient phenotype through the production of normal wild-
type Atp7a. Morpholino oligonuclotides lead to a restoration
of wild-type protein without detectable changes in the mRNA,
suggesting a competitive translational regulation (Madsen et al.,
2008).
Drosophila melanogaster has for several decades been one
of the most powerful in vivo genetic model organisms used to
describe molecular mechanisms of many biological pathways.
What is more, the simplicity of its nervous system has made
this small insect an especially valuable model in neurobiology.
Thus, the fruit fly has contributed to the identification of genes
and proteins underlying ‘‘molecular machinery’’ in the brain
of processes, such as learning, memory formation, sleep or
circadian rhythms. Moreover, since the nucleotide sequence of
D. melanogaster genome has been published, it is presumed
that approximately 10% of the genes common in both human
and fly are involved in neurological diseases (Greenspan and
Dierick, 2004). Therefore, D. melanogaster has also been used as a
model for neurodegenerative diseases, like Huntington’s disease,
Parkinson’s disease, Alzheimer’s disease and most recently
Menkes disease.
Research into Cu metabolism in Drosophila began over
50 years ago. However, during the last decade scientists
have particularly focused on the identification of regulatory
mechanisms for cellular Cu metabolism. It has been proved
that orthologs of the major eukaryotic Cu regulatory genes are
well conserved between mammals and insects. Cu transporters
and chaperons as well as a Cu-ATPase have been identified
in the fruit fly (Norgate et al., 2007; Kirby et al., 2008; Hua
et al., 2011). In contrast to mammals, D. melanogaster carries
only one Cu-transporting ATPase known as DmATP7. The
similarity between human ATP7A and ATP7B proteins is
roughly 60%. Nevertheless, motifs responsible for basolateral
targeting and retention of ATP7A are conserved in DmATP7,
whereas targeting motifs in ATP7B are not (Southon et al.,
2010). Similarly to human Cu-ATPases, DmATP7 is expressed
from early embryogenesis. In adult D. melanogaster DmATP7
is expressed at high levels in the digestive tract and the nervous
system (Norgate et al., 2006; Burke et al., 2008). DmATP7 seems
to play the same role as the mammalian orthologs and is essential
for Cu efflux in several D. melanogaster tissues (Southon et al.,
2004; Burke et al., 2008). Furthermore, high conservation of Cu-
ATPases between mammals and fruit fly permits the correction
of the Cu hyper-accumulation phenotype of cultured fibroblasts
from a Menkes disease patient carrying a null ATP7A mutation,
by the expression of DmATP7 (Southon et al., 2010). In the fruit
fly, the inhibition of DmATP7 expression in peptidergic neurons
shows that neuropeptide amidation is perturbed (Sellami et al.,
2012), and resemble that seen in the brindled mice, in which PAM
is impaired (Steveson et al., 2003; Niciu et al., 2007).
Norgate et al. (2006) established a classical D. melanogaster
model of Menkes disease with a null mutation. This mutant
seems extremely lethargic, which could be explained by the
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dysfunction of the Cu-dependent nervous system or respiratory
system. The mouth parts of the DmATP7−/− larva are smaller
and reduced in pigmentation compared to controls. Moreover
DmATP7−/− cell clones generated in control flies in the thorax
and abdomen are depigmented. These observations indicate that
DmATP7 supplies Cu to tyrosinase in D. melanogaster (Norgate
et al., 2006) similarly to zebrafish (Mendelsohn et al., 2006;
Madsen et al., 2008), mouse and humans (Petris et al., 2000).
Unfortunately, DmATP7−/− insects are unable to grow after
hatching and die early in development making it impossible to
examine adult mutants (Norgate et al., 2006).
To overcome this problem, most recently Bahadorani et al.
(2010) constructed a new Drosophila model of Menkes disease
by conditional silencing of DmATP7 only in the digestive tract.
Expression of a RNAi construct against DmATP7 was limited to
gut cells. As is the case in Menkes patients and mottled mice,
inhibiting the expression of DmATP7 in the intestine enhanced
lethality. It is hypothesized that the lethality of insects is the result
of reduced Cu level in the nervous system. This hypothesis has
been proposed on the basis of observations showing that the
brains of the model flies were smaller and contained less stainable
material when compared to control flies. Interestingly, roughly
50% of the flies survived to adulthood. However, in contrast to
the mottled mice, such flies exhibit normal morphology without
hypopigmentation or abnormalities of bristle hair-like structures.
The surviving adults can be compared to OHS patients. The life
span of such flies was only slightly shorter than that of control
flies. Such adult survivors were sensitized to the oxidative stress
of hyperoxia probably because of the reduced activity of SOD1
(Bahadorani et al., 2010). Reduction of SOD1 is also observed in
the brain of Menkes disease patients (Shibata et al., 1995), mutant
mice and D. rerio (Chen et al., 2011; Lenartowicz et al., 2014).
Studies on Drosophila Menkes disease model revealed MTF-1
as a potential therapeutic factor. The expression of MTF-1 in
gut-DmATP7-RNAi larva enhances their survival to adulthood.
A defensive mechanism probably involves the induction of
methallothioneines, which bind excess Cu accumulated in the
gut and prevent its toxic effect. The second scenario explains the
therapeutic effect by the induction of the Cu importer (Ctr1B)
expression, and thus the transfer of additional Cu to the tissues
(Bahadorani et al., 2010).
CONCLUDING REMARKS
To summarize, while murine models of Menkes disease
are well-established, non-mammalian models can be used
in experiments which are technically difficult to carry
out in mammals. The rapid external development of the
transparent zebrafish embryo permits a characterization
of developmental abnormalities and allows cellular and
genetic manipulations that are not possible during in utero
development. The models can be used for large-scale screening
for compounds that regulate Cu metabolism and could be
potential drugs for Menkes disease treatment. The animals
D. rerio and D. melanogaster are also invaluable to the
development of new therapeutic strategies utilizing synthetic
oligonucleotide analogs or the therapeutic effect of the MTF-1
protein.
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